Trial Profile
A 52-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms BEAM
- Sponsors Reata Pharmaceuticals
- 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
- 24 Jun 2011 Primary endpoint 'Glomerular-filtration-rate' has been met.
- 24 Jun 2011 Results published in the New England Journal of Medicine.